| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a36c66685971b78daf233b5999ead4c2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4433
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P23-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4433
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04 |
| filingDate |
2018-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26c88b6c0b0a03563ec5ab89503f857a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be2296e2e095f715ffd678d34892af2a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44f4e594ed520f5d7227ac88fb8656ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_459a5103e0f6d5ef28b01d02a4caa308 |
| publicationDate |
2020-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2018380173-A1 |
| titleOfInvention |
Use of KOR agonist in combination with MOR agonist in preparing drug for treating pain |
| abstract |
Disclosed is the use of a KOR agonist in combination with a MOR agonist in preparing a drug for treating pain. The KOR agonist is selected from a compound as shown in the general formula (I), and the MOR agonist is selected from a compound as shown in the general formula (II), wherein the definitions of each substituent in the general formula (I) and (II) are the same as defined in the description. |
| priorityDate |
2017-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |